Clinical significance of IL-18 gene over-expression in AML

Bin Zhang; Yong Wang; Guo Guang Zheng; Xiao Tong Ma; Ge Li; Feng Kui Zhang; Ke Fu Wu

doi:10.1016/S0145-2126(02)00025-5

Clinical significance of IL-18 gene over-expression in AML

Bin Zhang, Yong Wang, Guo Guang Zheng, Xiao Tong Ma, Ge Li, Feng Kui Zhang, Ke Fu Wu^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Little is known about the clinical significance of interleukin (IL)-18, a novel immunoregulatory cytokine, in acute myeloid leukemia (AML). Using reverse transcriptase polymerase chain reaction (RT-PCR) analysis, levels of IL-18 mRNA were assessed in bone marrow mononuclear cells (BMMC) from 47 adult patients with de novo or CR AML in order to explore the clinical significance of IL-18. The relationship between expression levels and the established prognostic factors such as age, cytogenetic aberrations, CD34 expression and FAB subtypes was investigated. Either disease status, age or CD34 expression were found to significantly correlate with the expression of IL-18. With respect to FAB cytotypes, expression of IL-18 gene in M4/M5 (n=15) was statistically higher than that in other subtypes (n=32, P<0.001). Moreover, a significant difference in IL-18 gene expression was obtained between the high risk group and the intermediate risk group (0.5627 versus 0.3111, P=0.038). In addition, a relationship between IL-18 expression of BMMC and initial white blood cell (WBC) was clearly demonstrated by a statistical analysis (r=0.806, P<0.001). These observations suggest that IL-18 gene over-expression might reflect the convergence of several important unfavorable prognostic factors in AML.

Original language	English (US)
Pages (from-to)	887-892
Number of pages	6
Journal	Leukemia Research
Volume	26
Issue number	10
DOIs	https://doi.org/10.1016/S0145-2126(02)00025-5
State	Published - 2002

Funding

This work was supported by the Chinese National Natural Sciences Foundation (Grant No. 39980014). We also thank Ms. Xiao-Jin Sha, Ms. Qing Rao, Ms.Yan-Ping Xue and Mr. Zhen-Yu Cao for their technical assistance. B. Zhang provided the concept, design, collected and analyzed the data, provided statistical expertise, drafted the manuscript, and gave final approval. Y. Wang contributed to the study design, gave technical support, provided critical input to the revision, and gave final approval as well as assisting in drafting the manuscript. G.-G. Zheng contributed to the analysis and drafting of the paper, provided input to the revision, provided funding, and gave final approval. X.-T. Ma provided technical support, helped to analyze the data, contributed to the drafting and revision of the manuscript, and gave final approval. G. Li provided technical support, helped with the analysis and the revision and gave final approval. F.-K. Zhang provided study materials, assisted with data interpretation, contributed to the review, and gave final approval. K.-F. Wu contributed to the study design, gave critical input to the revision, obtained funding and gave final approval.

Keywords

Acute myeloid leukemia
Gene expression
Interleukin-18
Prognostic factor

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0145-2126(02)00025-5

Cite this

@article{14998ecb90bf4ff285ec8bd390008054,

title = "Clinical significance of IL-18 gene over-expression in AML",

abstract = "Little is known about the clinical significance of interleukin (IL)-18, a novel immunoregulatory cytokine, in acute myeloid leukemia (AML). Using reverse transcriptase polymerase chain reaction (RT-PCR) analysis, levels of IL-18 mRNA were assessed in bone marrow mononuclear cells (BMMC) from 47 adult patients with de novo or CR AML in order to explore the clinical significance of IL-18. The relationship between expression levels and the established prognostic factors such as age, cytogenetic aberrations, CD34 expression and FAB subtypes was investigated. Either disease status, age or CD34 expression were found to significantly correlate with the expression of IL-18. With respect to FAB cytotypes, expression of IL-18 gene in M4/M5 (n=15) was statistically higher than that in other subtypes (n=32, P<0.001). Moreover, a significant difference in IL-18 gene expression was obtained between the high risk group and the intermediate risk group (0.5627 versus 0.3111, P=0.038). In addition, a relationship between IL-18 expression of BMMC and initial white blood cell (WBC) was clearly demonstrated by a statistical analysis (r=0.806, P<0.001). These observations suggest that IL-18 gene over-expression might reflect the convergence of several important unfavorable prognostic factors in AML.",

keywords = "Acute myeloid leukemia, Gene expression, Interleukin-18, Prognostic factor",

author = "Bin Zhang and Yong Wang and Zheng, {Guo Guang} and Ma, {Xiao Tong} and Ge Li and Zhang, {Feng Kui} and Wu, {Ke Fu}",

note = "Funding Information: This work was supported by the Chinese National Natural Sciences Foundation (Grant No. 39980014). We also thank Ms. Xiao-Jin Sha, Ms. Qing Rao, Ms.Yan-Ping Xue and Mr. Zhen-Yu Cao for their technical assistance. B. Zhang provided the concept, design, collected and analyzed the data, provided statistical expertise, drafted the manuscript, and gave final approval. Y. Wang contributed to the study design, gave technical support, provided critical input to the revision, and gave final approval as well as assisting in drafting the manuscript. G.-G. Zheng contributed to the analysis and drafting of the paper, provided input to the revision, provided funding, and gave final approval. X.-T. Ma provided technical support, helped to analyze the data, contributed to the drafting and revision of the manuscript, and gave final approval. G. Li provided technical support, helped with the analysis and the revision and gave final approval. F.-K. Zhang provided study materials, assisted with data interpretation, contributed to the review, and gave final approval. K.-F. Wu contributed to the study design, gave critical input to the revision, obtained funding and gave final approval.",

year = "2002",

doi = "10.1016/S0145-2126(02)00025-5",

language = "English (US)",

volume = "26",

pages = "887--892",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "10",

}

TY - JOUR

T1 - Clinical significance of IL-18 gene over-expression in AML

AU - Zhang, Bin

AU - Wang, Yong

AU - Zheng, Guo Guang

AU - Ma, Xiao Tong

AU - Li, Ge

AU - Zhang, Feng Kui

AU - Wu, Ke Fu

N1 - Funding Information: This work was supported by the Chinese National Natural Sciences Foundation (Grant No. 39980014). We also thank Ms. Xiao-Jin Sha, Ms. Qing Rao, Ms.Yan-Ping Xue and Mr. Zhen-Yu Cao for their technical assistance. B. Zhang provided the concept, design, collected and analyzed the data, provided statistical expertise, drafted the manuscript, and gave final approval. Y. Wang contributed to the study design, gave technical support, provided critical input to the revision, and gave final approval as well as assisting in drafting the manuscript. G.-G. Zheng contributed to the analysis and drafting of the paper, provided input to the revision, provided funding, and gave final approval. X.-T. Ma provided technical support, helped to analyze the data, contributed to the drafting and revision of the manuscript, and gave final approval. G. Li provided technical support, helped with the analysis and the revision and gave final approval. F.-K. Zhang provided study materials, assisted with data interpretation, contributed to the review, and gave final approval. K.-F. Wu contributed to the study design, gave critical input to the revision, obtained funding and gave final approval.

PY - 2002

Y1 - 2002

N2 - Little is known about the clinical significance of interleukin (IL)-18, a novel immunoregulatory cytokine, in acute myeloid leukemia (AML). Using reverse transcriptase polymerase chain reaction (RT-PCR) analysis, levels of IL-18 mRNA were assessed in bone marrow mononuclear cells (BMMC) from 47 adult patients with de novo or CR AML in order to explore the clinical significance of IL-18. The relationship between expression levels and the established prognostic factors such as age, cytogenetic aberrations, CD34 expression and FAB subtypes was investigated. Either disease status, age or CD34 expression were found to significantly correlate with the expression of IL-18. With respect to FAB cytotypes, expression of IL-18 gene in M4/M5 (n=15) was statistically higher than that in other subtypes (n=32, P<0.001). Moreover, a significant difference in IL-18 gene expression was obtained between the high risk group and the intermediate risk group (0.5627 versus 0.3111, P=0.038). In addition, a relationship between IL-18 expression of BMMC and initial white blood cell (WBC) was clearly demonstrated by a statistical analysis (r=0.806, P<0.001). These observations suggest that IL-18 gene over-expression might reflect the convergence of several important unfavorable prognostic factors in AML.

AB - Little is known about the clinical significance of interleukin (IL)-18, a novel immunoregulatory cytokine, in acute myeloid leukemia (AML). Using reverse transcriptase polymerase chain reaction (RT-PCR) analysis, levels of IL-18 mRNA were assessed in bone marrow mononuclear cells (BMMC) from 47 adult patients with de novo or CR AML in order to explore the clinical significance of IL-18. The relationship between expression levels and the established prognostic factors such as age, cytogenetic aberrations, CD34 expression and FAB subtypes was investigated. Either disease status, age or CD34 expression were found to significantly correlate with the expression of IL-18. With respect to FAB cytotypes, expression of IL-18 gene in M4/M5 (n=15) was statistically higher than that in other subtypes (n=32, P<0.001). Moreover, a significant difference in IL-18 gene expression was obtained between the high risk group and the intermediate risk group (0.5627 versus 0.3111, P=0.038). In addition, a relationship between IL-18 expression of BMMC and initial white blood cell (WBC) was clearly demonstrated by a statistical analysis (r=0.806, P<0.001). These observations suggest that IL-18 gene over-expression might reflect the convergence of several important unfavorable prognostic factors in AML.

KW - Acute myeloid leukemia

KW - Gene expression

KW - Interleukin-18

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=0036348548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036348548&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(02)00025-5

DO - 10.1016/S0145-2126(02)00025-5

M3 - Article

C2 - 12163048

AN - SCOPUS:0036348548

SN - 0145-2126

VL - 26

SP - 887

EP - 892

JO - Leukemia Research

JF - Leukemia Research

IS - 10

ER -

Clinical significance of IL-18 gene over-expression in AML

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this